您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2021, Vol. 59 ›› Issue (9): 64-71.doi: 10.6040/j.issn.1671-7554.0.2021.1091

• 专家综述 • 上一篇    下一篇

肿瘤液体活检

王传新1,2   

  1. 1.山东大学第二医院检验医学中心, 山东 济南 250033;2.山东省肿瘤标志物检测工程实验室, 山东 济南 250033
  • 发布日期:2021-10-15
  • 通讯作者: 王传新. E-mail:cxwang@sdu.edu.cn
  • 基金资助:
    国家自然科学基金重点项目(21020307182549500);山东省重点研发计划国际合作项目(2019GHZ003)

Liquid biopsy of tumor

WANG Chuanxin1,2   

  1. 1. Department of Clinical Laboratory, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250033, Shandong, China;
    2. Tumor Marker Detection Engineering Laboratory of Shandong Provine, Jinan 250033, Shandong, China
  • Published:2021-10-15

RichHTML

7

PDF (PC)

404

摘要： 肿瘤是危害人类健康的重大疾病,其复杂性和异质性使得肿瘤诊疗进展缓慢。精准医疗促使肿瘤诊疗方式朝着更加精细化、个体化的方向发展,分子诊断技术和靶向治疗正逐步应用于肿瘤临床诊疗过程。液体活检技术能够通过患者体液反映疾病状态,无创且能提供动态丰富的肿瘤相关分子信息,在肿瘤早期预警及辅助诊断、疗效实时监测、用药指导和耐药机制探索、预后判断和风险分级、靶向药物伴随诊断等方面具有巨大应用潜能,受到临床的广泛关注。论文将针对液体活检的分类、临床应用及未来发展等方面,综述液体活检在肿瘤精准诊疗中的最新进展。

关键词: 肿瘤, 液体活检, 分子诊断, 临床应用, 精准医疗

Abstract: Tumor, whose complexity and heterogeneity make the progress of tumor diagnosis and treatment slow, is damaging human life and health. Precision medicine promotes the development of tumor diagnosis and treatment in a more refined and individual direction, and molecular diagnostic techniques and targeted therapy are gradually being applied in the clinical diagnosis and treatment of tumors. Liquid biopsy can reflect disease status through a patients body fluids. It is noninvasive and able to provide dynamic and rich molecular information, thus, it has great potential in the early detection and auxiliary diagnosis, real time monitoring of treatment efficacy, guidance of drug use and exploration of mechanism in drug resistance, prognosis and risk stratification, and concomitant diagnosis of targeted drugs. This review will focus on the classification, clinical application, as well as future challenges of liquid biopsy in precision oncology and introduce the latest development.

Key words: Tumor, Liquid biopsy, Molecule diagnostics, Clinical application, Precision medicine

中图分类号: 

  • R446.9
[1] Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: Towards implementation of circulating tumour DNA [J]. Nat Rev Cancer, 2017, 17(4): 223-238.
[2] Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctdna analysis depicts early-stage lung cancer evolution [J]. Nature, 2017, 545(7655): 446-451.
[3] Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death [J]. Aust Med J, 1969, 14(14): 146-147.
[4] Xia WX, Li HD, Li YQ, et al. In vivo coinstantaneous identification of hepatocellular carcinoma circulating tumor cells by dual-targeting magnetic-fluorescent nanobeads [J]. Nano Lett, 2021, 21(1): 634-641.
[5] Herath S, Razavi Bazaz S, Monkman J, et al. Circulating tumor cell clusters: insights into tumour dissemination and metastasis [J]. Expert Rev Mol Diagn, 2020, 20(11): 1139-1147.
[6] Luo Q, Wang CM, Peng BJ, et al. Circulating tumor-cell-associated white blood cell clusters in peripheral blood indicate poor prognosis in patients with hepatocellular carcinoma [J]. Front Oncol, 2020, 10: 1758. doi:10.3389/fonc.2020.01758.
[7] Smolkova B, Cierna Z, Kalavska K, et al. Increased stromal infiltrating lymphocytes are associated with the risk of disease progression in mesenchymal circulating tumor cell-positive primary breast cancer patients [J]. Int J Mol Sci, 2020, 21(24): 9460.
[8] Pantel K, Speicher MR. The biology of circulating tumor cells [J]. Oncogene, 2016, 35(10): 1216-1224.
[9] Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells [J]. Am J Pathol, 2000, 156(1): 57-63.
[10] Riethdorf S, Fritsche H, Müller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cellsearch system [J]. Clin Cancer Res, 2007, 13(3): 920-928.
[11] Spellman PT, Gray JW. Detecting cancer by monitoring circulating tumor DNA [J]. Nat Med, 2014, 20(5): 474-475.
[12] Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis [J]. J Mol Med(Berl), 2013, 91(4): 431-437.
[13] Greening DW, Xu R, Ji H, et al. A protocol for exosome isolation and characterization: evaluation of ultracentrifugation, density-gradient separation, and immunoaffinity capture methods [J]. Methods Mol Biol, 2015, 1295: 179-209. doi:10.1007/978-1-4939-2550-6_15.
[14] Saaoud F, Drummer IVC, Shao Y, et al. Circular rnas are a novel type of non-coding rnas in ros regulation, cardiovascular metabolic inflammations and cancers [J]. Pharmacol Ther, 2020: 107715. doi:10.1016/j.pharmthera.2020.107715.
[15] Xie Y, Li J, Li P, et al. Rna-seq profiling of serum exosomal circular rnas reveals circ-pnn as a potential biomarker for human colorectal cancer [J]. Front Oncol, 2020, 10: 982. doi:10.3389/fonc.2020.00982.
[16] Zhao Y, Du T, Du L, et al. Long noncoding rna linc02418 regulates melk expression by acting as a cerna and may serve as a diagnostic marker for colorectal cancer [J]. Cell Death Dis, 2019, 10(8): 568.
[17] Katz RL, He W, Khanna A, et al. Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study [J]. Clin Cancer Res, 2010, 16(15): 3976-3987.
[18] Katz RL, Zaidi TM, Pujara D, et al. Identification of circulating tumor cells using 4-color fluorescence in situ hybridization: Validation of a noninvasive aid for ruling out lung cancer in patients with low-dose computed tomography-detected lung nodules [J]. Cancer Cytopathol, 2020, 128(8): 553-562.
[19] Goveia J, Rohlenova K, Taverna F, et al. An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates [J]. Cancer Cell, 2020, 37(3): 421.
[20] Brinkman K, Meyer L, Bickel A, et al. Extracellular vesicles from plasma have higher tumour rna fraction than platelets [J]. J Extracell Vesicles, 2020, 9(1): 1741176.
[21] Best MG, Sol N, In 't Veld SGJG, et al. Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets [J]. Cancer Cell, 2017, 32(2): 238-252.
[22] Paweletz CP, Sacher AG, Raymond CK, et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients [J]. Clin Cancer Res, 2016, 22(4): 915-922.
[23] Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test [J]. Science, 2018, 359(6378): 926-930.
[24] Cohen JD, Javed AA, Thoburn C, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers [J]. PNAS, 2017, 114(38): 10202-10207.
[25] Kaiser J. ‘Liquid biopsy’ for cancer promises early detection [J]. Science, 2018, 359(6373): 259.
[26] Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy [J]. Cancer Discov, 2016, 6(5): 479-491.
[27] Sanmamed MF, Fernández-Landázuri S, Rodríguez C, et al. Quantitative cell-free circulating brafv600e mutation analysis by use of droplet digital pcr in the follow-up of patients with melanoma being treated with braf inhibitors [J]. Clin Chem, 2015, 61(1): 297-304.
[28] Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in egfr-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA [J]. Clin Cancer Res, 2014, 20(6): 1698-1705.
[29] Geoffrey RO, Alexander ED, Manisha HS, et al. Detection and clearance of RET variants in plasma cell free DNA(cfDNA)from patients(pts)treated with loxo-292. [J]. J Clin Oncol, 2018, 36(15): 9048-9048.
[30] Frances AS, Papadimitrakopoulou V, Tony M, et al. Early clearance of plasma egfr mutations as a predictor of response to osimertinib in the aura3 trial. [J]. J Clin Oncol, 2018, 36(15): 9027-9027.
[31] Hyman DM, Smyth LM, Donoghue MTA, et al. Akt inhibition in solid tumors with akt1 mutations [J]. J Clin Oncol, 2017, 35(20): 2251-2259.
[32] Choudhury AD, Werner L, Francini E, et al. Tumor fraction in cell-free DNA as a biomarker in prostate cancer [J]. JCI Insight, 2018, 3(21): 122109.
[33] Goodall J, Assaf ZJ, Shi Z, et al. Circulating tumor DNA(ctdna)dynamics associate with treatment response and radiological progression-free survival(rpfs): Analyses from a randomized phase ii trial in metastatic castration-resistant prostate cancer(mcrpc)[J]. J Clin Oncol, 2020, 38(15): 5508-5508.
[34] Zheng MM, Li YS, Tu HY, et al. Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in egfr-mutated nsclc [J]. J Thorac Oncol, 2021, 16(2): 250-258.
[35] Ococks E, Frankell AM, Masque Soler N, et al. Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling [J]. Ann Oncol, 2021, 32(4): 522-532.
[36] 林铖, 姜傥. 液体活检技术在非小细胞肺癌患者EGFR-TKI继发耐药中的应用 [J]. 检验医学, 2016, 31(10): 835-843. LIN Cheng, JIANG Tang. Liquid biopsy for monitoring EGFR-TKI drug resistance in patients with non-small-cell lung cancer [J]. Laboratory Medicine, 2016, 31(10): 835-843.
[37] 刘志刚, 施奇惠. 基于液体活检与二代测序解析肺腺癌患者靶向药耐药机制[J]. 基因组学与应用生物学, 2021, 40(3): 1348-1355. LIU Zhigang, SHI Qihui.Deciphering resistance mechanism of targeted therapy in lung adenocarcinoma patients based on liquid biopsy and next-generation sequencing [J]. Genomics and Applied Biology, 2021, 40(3): 1348-1355.
[38] Castellanos-Rizaldos E, Grimm DG, Tadigotla V, et al. Exosome-based detection of egfr t790m in plasma from non-small cell lung cancer patients [J]. Clin Cancer Res, 2018, 24(12): 2944-2950.
[39] Hur JY, Kim HJ, Lee JS, et al. Extracellular vesicle-derived DNA for performing egfr genotyping of nsclc patients [J]. Mol Cancer, 2018, 17(1): 15.
[40] Sundaresan TK, Sequist LV, Heymach JV, et al. Detection of t790m, the acquired resistance egfr mutation, by tumor biopsy versus noninvasive blood-based analyses [J]. Clin Cancer Res, 2016, 22(5): 1103-1110.
[41] Zheng D, Ye X, Zhang MZ, et al. Plasma egfr t790m ctdna status is associated with clinical outcome in advanced nsclc patients with acquired egfr-tki resistance [J]. Sci Rep, 2016, 6: 20913. doi:10.1038/srep20913.
[42] Mao C, Yuan JQ, Yang ZY, et al. Blood as a substitute for tumor tissue in detecting egfr mutations for guiding egfr tkis treatment of nonsmall cell lung cancer: A systematic review and meta-analysis [J]. Medicine(Baltimore), 2015, 94(21): e775.
[43] Best MG, Sol N, Kooi I, et al. Rna-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics [J]. Cancer Cell, 2015, 28(5): 666-676.
[44] Hrebien S, Citi V, Garcia-Murillas I, et al. Early ctdna dynamics as a surrogate for progression-free survival in advanced breast cancer in the beech trial [J]. Ann Oncol, 2019, 30(6): 945-952.
[45] Goldberg SB, Narayan A, Kole AJ, et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA [J]. Clin Cancer Res, 2018, 24(8): 1872-1880.
[46] Santiago-Walker A, Gagnon R, Mazumdar J, et al. Correlation of braf mutation status in circulating-free DNA and tumor and association with clinical outcome across four brafi and meki clinical trials [J]. Clin Cancer Res, 2016, 22(3): 567-574.
[47] Pietrasz D, Pécuchet N, Garlan F, et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker [J]. Clin Cancer Res, 2017, 23(1): 116-123.
[48] Lapin M, Oltedal S, Tjensvoll K, et al. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer [J]. J Transl Med, 2018, 16(1): 300.
[49] Bernard V, Kim DU, San Lucas FA, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer [J]. Gastroenterology, 2019, 156(1): 108-118.
[50] Nanou A, Mol L, Coumans FAW, et al. Endothelium-derived extracellular vesicles associate with poor prognosis in metastatic colorectal cancer [J]. Cells, 2020, 9(12): 2688.
[51] 中国临床肿瘤学会非小细胞肺癌专家委员会. 二代测序技术在NSCLC中的临床应用中国专家共识(2020版)[J]. 中国肺癌杂志, 2020, 23(9): 741-761.
[52] 中华医学会检验医学分会, 国家卫生健康委员会临床检验中心. 液体活检在临床肿瘤诊疗应用和医学检验实践中的专家共识[J]. 中华检验医学杂志, 2018, 41(10): 724-733.
[53] Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J]. Genome Med, 2017, 9(1): 34.
[54] Oliveira AF, Bretes L, Furtado I. Review of pd-1/pd-l1 inhibitors in metastatic dmmr/msi-h colorectal cancer [J]. Front Oncol, 2019, 9: 396. doi:10.3389/fonc.2019.00396.
[1] 王伟 王沂峰 张岭梅 林琼燕 黄菊. 人卵巢癌OVCAR3细胞系中侧群细胞的分离及其成瘤性、侵袭性的实验研究[J]. 山东大学学报(医学版), 2209, 47(6): 8-11.
[2] 李波波 李道堂 刘曙光 王兴武. 食管癌患者血清中DKK-1的表达[J]. 山东大学学报(医学版), 2209, 47(6): 58-61.
[3] 鹿向东 杨伟 徐广明 曲元明. 脑膜瘤中PPAR-γ的表达及曲格列酮对脑膜瘤培养细胞生长的影响[J]. 山东大学学报(医学版), 2209, 47(6): 65-.
[4] 黄方 康瑞 吴春林. VEGFC、NF-κBp65及Survivin在鼻咽癌中的表达及临床意义[J]. 山东大学学报(医学版), 2209, 47(6): 83-.
[5] 张士宝 刘庆勇 阮喜云 陈杰 张建军 李宗武 杨广笑 王全颖. NT4-SAC-HA2-TAT融合基因表达载体的构建及鉴定[J]. 山东大学学报(医学版), 2209, 47(6): 15-19.
[6] 王丽慧,高敏,孔北华. 子宫血管肉瘤2例报告并文献复习[J]. 山东大学学报 (医学版), 2022, 60(9): 108-112.
[7] 马翔,赵飞燕. 卵子冷冻保存现状与进展[J]. 山东大学学报 (医学版), 2022, 60(9): 19-23.
[8] 孙文雄,吴日超,郑贤静,李丽, 张友忠. 宫颈血管周上皮样细胞肿瘤1例[J]. 山东大学学报 (医学版), 2022, 60(9): 125-128.
[9] 吴瑞芳,李长忠. 女性生育力保护的现状与进展[J]. 山东大学学报 (医学版), 2022, 60(9): 1-7.
[10] 张艺馨,赵玉立,封丽. 超声特征及术前CA-125联合对51例卵巢交界性及Ⅰ期恶性肿瘤的鉴别诊断[J]. 山东大学学报 (医学版), 2022, 60(7): 104-109.
[11] 李琳琳,王凯. 基于生物信息学预测肝细胞癌预后基因[J]. 山东大学学报 (医学版), 2022, 60(5): 50-58.
[12] 宋钰峰,宁豪,姚志刚,吴海虎,刘非凡,吕家驹. 肾上腺海绵状血管瘤临床及影像特征[J]. 山东大学学报 (医学版), 2022, 60(2): 37-42.
[13] 程传龙,杨淑霞,佘凯丽,房启迪,韩闯,刘盈,崔峰,李秀君. 淄博市2018年恶性肿瘤的流行特征及影响因素[J]. 山东大学学报 (医学版), 2022, 60(2): 102-108.
[14] 亓梦雨,周敏然,孙洺山,李世洁,陈春燕. T大颗粒淋巴细胞白血病合并原发性骨髓纤维化1例[J]. 山东大学学报 (医学版), 2022, 60(2): 118-120.
[15] 许英杰,吕洪涛,荣风年. 妊娠期外阴血管肌纤维母细胞瘤1例[J]. 山东大学学报 (医学版), 2022, 60(11): 130-132.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 张杰,李振华,孙晋浩,暴丽华,刘岳鹏. 恒定磁场对Schwann细胞氧化损伤的保护作用[J]. 山东大学学报(医学版), 2007, 45(3): 229 -232 .
[2] 李明霞,王学禹 . 儿童急性播散性脑脊髓炎31例临床与MRI特点[J]. 山东大学学报(医学版), 2008, 46(8): 828 -830 .
[3] . Graves病131治疗后1年内早发甲减影响因素分析[J]. 山东大学学报(医学版), 2009, 47(9): 5 -6 .
[4] 牛瑞,刘波,邵明举,王伟 . 非小细胞肺癌区域淋巴结中肺组织特异性基因的表达与预后的关系[J]. 山东大学学报(医学版), 2007, 45(9): 884 -885 .
[5] 方英立,马玉燕,刘锡梅,周文 . 急诊剖宫产患者围手术期替硝唑合理应用[J]. 山东大学学报(医学版), 2007, 45(10): 995 .
[6] 姜红菊,李润智,王营,徐冬梅,张梅,张运,李继福 . 冠状动脉粥样硬化斑块形态及介入治疗与MMP-9的关系[J]. 山东大学学报(医学版), 2008, 46(10): 966 -970 .
[7] 焦芳芳,刘世青,李飞,李长生,王琴,孙青,鹿伟 . 化瘀理肺方对大鼠肺间质纤维化时Smad7和TGF-β表达的影响[J]. 山东大学学报(医学版), 2007, 45(10): 1054 -1058 .
[8] 赵瑛，颜磊，张辉，于鹏，李明江，赵兴波. 精子相关抗原9在卵巢浆液性上皮肿瘤中的表达[J]. 山东大学学报(医学版), 2012, 50(2): 98 .
[9] 徐金娥1,2，王珊1，赵跃然1，陈子江1. 蜕膜组织杀伤细胞免疫球蛋白样受体与不明原因早期复发性流产的相关性[J]. 山东大学学报(医学版), 2009, 47(12): 81 -85 .
[10] 郑敏,郝跃伟,刘雪平,赵婷婷. 血小板膜糖蛋白Ibα基因HPA-2、Kozak序列多态性与脑梗死的相关性研究[J]. 山东大学学报(医学版), 2008, 46(3): 292 -295 .
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发